4D Molecular Therapeutics filings document financial results, clinical-development disclosures and governance matters for a Nasdaq-listed biotechnology issuer. Form 8-K reports furnish quarterly and annual results and include pipeline updates for 4D-150, the 4FRONT program in wet AMD, and related PRISM and SPECTRA studies in retinal disease.
The company’s proxy materials cover director elections, auditor ratification and executive-compensation votes. Other filings disclose officer appointments and compensatory arrangements, equity awards, registered common stock, and capital-structure actions involving exchanges of common stock for pre-funded warrants with exercise limitations and beneficial-ownership blockers.
4D Molecular Therapeutics, Inc. reported positive 2-year data from the PRISM Phase 2b clinical trial evaluating its product candidate 4D-150 in a broad wet age-related macular degeneration population, based on a data cutoff of May 18, 2026. The disclosure highlights trial and patient cohort overview information, Phase 2b efficacy results through 2 years, and safety data for the selected Phase 3 dose across the overall PRISM Phase 1/2a and 2b clinical trial population of 71 patients.
The company explains that statements about the therapeutic potential, treatment-burden reduction, durability and success of clinical trials for 4D-150 are forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties described in its most recent quarterly report filed on May 7, 2026, and the company disclaims any obligation to update forward-looking statements.
4D Molecular Therapeutics, Inc. director and officer David Kirn reported three open-market sales totaling 58,333 shares of common stock on July 9–10, 2026, at weighted average prices of $12.8656, $12.8355 and $12.0107 per share under a Rule 10b5-1 trading plan. After these transactions, he directly holds 884,152 shares of FDMT common stock.
FDMT received a Form 144 notice covering a proposed sale of 15,725 shares of Class A Common stock by Goldman Sachs & Co. LLC. The shares were acquired from the issuer in a private transaction on 12/15/2020, and the planned sale date is 07/10/2026.
The notice cites an aggregate market value of $193,574.75 for the shares to be sold, with 52,276,254 shares of Class A Common stated as outstanding. It also lists prior sales by David Kirn over the past three months, including 1,922 shares on 06/01/2026, 114,746 shares on 06/22/2026, and 42,608 shares on 07/09/2026.
David Kirn, an officer of 4D Molecular Therapeutics, Inc. (FDMT), plans to sell 42,608 Class A common shares, with an aggregate market value of $549,217.12 and an approximate sale date of July 9, 2026. Goldman Sachs & Co. LLC is listed as broker. The sale is connected to a selling plan dated January 9, 2026, intended to comply with Rule 10b5-1(c).
Kirn also sold 1,922 shares for gross proceeds of $19,257.86 on June 1, 2026, and 114,746 shares for gross proceeds of $1,200,851.31 on June 22, 2026.
4D Molecular Therapeutics Chief Legal Officer Scott Bizily reported an option exercise-and-sale transaction in company stock. On June 30, 2026, he sold 6,566 shares of common stock at $14.00 per share in an open-market transaction made pursuant to a Rule 10b5-1 trading plan adopted on January 13, 2026.
On the same date, he exercised stock options covering 5,752 shares at an exercise price of $6.49 per share and 814 shares at $4.14 per share, converting these derivative awards into common shares. The options exercised were from grants originally scheduled to vest monthly over four years and carried expiration dates in 2032 and 2035.
Scott Bizily, an officer of 4D Molecular Therapeutics, Inc. (FDMT), reported a proposed sale of 6,566 common shares, with an approximate sale date of June 30, 2026, and an aggregate market value of $84,570.08. The past-three-month sales record lists 9,810 common shares sold on June 23, 2026, for gross proceeds of $117,720.00, under the heading “10b5-1 Sales for Scott Bizily.”
4D Molecular Therapeutics, Inc. entered into a new senior secured Loan and Security Agreement with Hercules Capital providing term loans in an aggregate principal amount of up to $200.0 million. The facility matures on June 1, 2031 and is structured in multiple tranches, including a Tranche 1A Loan of $20.0 million drawn at closing, a Tranche 1B Loan of $30.0 million available at the company’s election until June 15, 2027, and additional milestone-based tranches totaling $100.0 million plus a discretionary $50.0 million tranche.
Tranche 1A bears interest at the greater of the prime rate plus 2.00% or 8.75%, while the other tranches bear the greater of the prime rate plus 2.50% or 9.25%, all payable monthly in arrears and capped at 0.75% above the rate in effect on funding. The company must pay a $500,000 Initial Facility Charge and a 1.00% Tranche Facility Charge on advances from Tranche 2 through Tranche 5.
The agreement includes minimum cash covenants tied to outstanding obligations and company market capitalization, a performance covenant triggered after FDA approval of the lead product candidate and borrowings of at least $75.0 million, and events of default that can accelerate all obligations. The loans are secured by substantially all company assets, including intellectual property, and certain future subsidiaries may be required to guarantee and pledge their assets.
4D Molecular Therapeutics Chief Legal Officer Scott Bizily reported an exercise-and-sell stock transaction. On June 23, 2026, he exercised options to acquire 9,810 shares of common stock at $4.14 per share, then sold 9,810 shares in an open-market trade at $12.00 per share.
After these transactions, he holds 8,617 common shares directly and 63,785 stock options with a $4.14 exercise price expiring in 2035. A footnote also notes 5,023 shares previously purchased under the company’s Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3.
Officer Scott Bizily reported a proposed sale of 9,810 common shares of 4D Molecular Therapeutics, Inc. (FDMT), with an approximate sale date of June 23, 2026, and an aggregate market value of $102,220.20. He acquired 9,810 shares from the issuer through exercise of stock options on June 23, 2026, paying cash. If relying on Rule 10b5-1, the stated plan-adoption or instruction date is January 13, 2026.
4D Molecular Therapeutics director and officer David Kirn reported an open-market sale of 114,746 shares of Common Stock at a weighted average price of $10.4653 per share. The transaction was executed under a Rule 10b5-1 trading plan adopted on January 9, 2026, meaning it was pre-scheduled rather than timed discretionarily. After this sale, Kirn directly holds 942,485 shares of the company’s stock.